The field of bioprinting is rapidly evolving, with bioinks playing a crucial role in the development of 3D printed living tissues. Bioinks, which incorporate live cells and bioactive molecules, are essential for creating tissue models that can revolutionize medicine, biology, and personalized
In a significant step toward understanding and combating childhood cancers and congenital disorders, the Gabriella Miller Kids First Pediatric Research Program (Kids First), an initiative of the National Institutes of Health (NIH), has released two comprehensive new datasets. Focusing on childhood
In an unexpected turn of events that sent ripples through the biotechnology sector, Pliant Therapeutics' shares experienced a dramatic plunge after the company voluntarily halted the Phase 2b/3 trial of its experimental fibrosis drug, bexotegrast. The decision, advised by a clinical trial
Fosun Pharmaceutical, a leading Chinese pharmaceutical conglomerate, recently attempted to take full control of its biopharma subsidiary, Henlius Biotech, by purchasing the remaining minority shares. This strategic move aimed to consolidate Henlius under Fosun's complete ownership, leveraging the
Boehringer Ingelheim has made significant strides in their research on progressive pulmonary fibrosis (PPF) with the successful results of their Phase III FIBRONEER™-ILD trial. This trial marks a critical milestone for Nerandomilast, an investigational oral preferential inhibitor of
The recent Orphan Drug Designation (ODD) granted by the U.S. Food and Drug Administration (FDA) to Zai Lab Limited for their drug ZL-1310 marks a significant milestone in the fight against small cell lung cancer (SCLC). This promising Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC) is
The 21st century has seen the pharmaceutical industry face mounting challenges such as escalating competition and pricing pressures. Consequently, developers and manufacturers are pioneering innovative strategies to differentiate their products and instill value, particularly in the saturated
In a groundbreaking development, the recent trials of a drug developed by Ireland-based psychedelics biotech company GH Research have showcased its potential in treating treatment-resistant depression. The mid-stage clinical trial, comprising 81 participants, revealed a significant reduction in
As the biopharma and life sciences sector maneuvers through a turbulent economic landscape, organizations face the daunting challenge of balancing costs with the need to attract and retain top talent. This industry-specific balancing act becomes all the more critical as we look ahead to the year
The latest study from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center provides compelling evidence that CAR T cell therapy does not induce secondary cancers. This finding comes from an extensive analysis of data involving over 700
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy